Apogee Therapeutic

Q2 FY2026 EarningsQ2 FY26 results were secondary to the headline announcement of a definitive agreement for AbbVie to acquire the company for $135.11 per share in cash. Financially, the net loss of $85.9M was wider than the $70.5M consensus, primarily due to increased R&D and G&A expenses to support pipeline expansion and $4.4M in merger transaction costs. While zero revenue was reported vs. a $10M consensus, the cash position remains robust at $1.3B, further bolstered by a $1.3B Blackstone financing collaboration.